APA (7th ed.) Citation

Wu, J., Wang, Z., Zhao, Z., Li, Q., Li, Z., & Li, Y. (2023). 152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL. Diseases of the Esophagus, 36, 1. https://doi.org/10.1093/dote/doad052.032

Chicago Style (17th ed.) Citation

Wu, Jia-Di, Zhi-Qiang Wang, Ze-Rui Zhao, Qiao-Qiao Li, Zhi-Chao Li, and Yu-Hong Li. "152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL." Diseases of the Esophagus 36 (2023): 1. https://doi.org/10.1093/dote/doad052.032.

MLA (9th ed.) Citation

Wu, Jia-Di, et al. "152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL." Diseases of the Esophagus, vol. 36, 2023, p. 1, https://doi.org/10.1093/dote/doad052.032.